[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-angioedema---type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-angioedema---type-2":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625889","phase-3-phase-3-extension-study-of-adx-324-in-participants-with-hereditary-angioedema-hae-100625889",false,"NCT07428499","Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)","A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema","Inclusion Criteria:\n\n* Have a documented diagnosis of HAE (Type I or II)\n* Completed Study ADX-324-301\n* Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)\n\nExclusion Criteria:\n\n* A negative reaction to study drug in ADX-324-301","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.",[26,27,28,29],"Hereditary Angioedema (HAE)","Hereditary Angioedema - Type 1","Hereditary Angioedema - Type 2","HAE",[31,29,32,33],"Hereditary angioedema","ADX-324","onvuzosiran","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-04-02",{"date":42,"type":20},"2030-06-30",{"name":44,"class":45},"ADARx Pharmaceuticals, Inc.","INDUSTRY",48,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100589884","phase-3-stop-hae-a-phase-3-study-of-adx-324-in-hae-100589884","NCT06960213","STOP-HAE: A Phase 3 Study of ADX-324 in HAE","STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema","STOP-HAE","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing informed consent.\n* Have a documented diagnosis of HAE-1\u002FHAE-2 (Type I or II)\n* Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening\n* Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)\n\nKey Exclusion Criteria:\n\n* Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).\n* Any clinically significant renal disease\n* Any clinically significant hepatic disease\n* Have used any of the following for long-term prevention of HAE attacks:\n\n  1. C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.\n  2. Berotralstat (ORLADEYO) within 3 weeks prior to Screening.\n  3. Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.\n  4. Androgen use within 12 weeks prior to Screening.\n* Received prior treatment with any RNA\u002FDNA-based therapy for HAE or intolerant to any prior RNA\u002FDNA-based therapy for any condition, excluding vaccines.",{"count":19,"type":20},[23],"This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.",[59,29,27,28],"Hereditary Angioedema",[29,31,33],{"date":37,"type":38},{"date":63,"type":38},"2025-08-28",{"date":65,"type":20},"2027-12-31",{"name":44,"class":45},51,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100627403","real-life-ecological-momentary-assessment-of-lived-burden-in-hereditary-angioedema-100627403","NCT07448181","Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema","REAL-HAE","Inclusion Criteria:\n\n* Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema;\n* Age ≥ 18 years;\n* Ability to understand instructions and provide informed consent;\n* Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS);\n* Willingness to participate in the study for the entire duration of the observation period (8 weeks).\n\nExclusion Criteria:\n\n* Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency;\n* Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently;\n* Age \\\u003C 18 years;",{"count":76,"type":20},30,"OBSERVATIONAL","The aim of this study is to conduct an in-depth analysis of the Burden of Disease (BoD) perceived by patients with Hereditary Angioedema (HAE), through daily prospective observations based on Ecological Momentary Assessment (EMA) via digital surveys and standardised questionnaires.\n\nParticipants will answer online survey questions about their perceived burden of disease for 8 consecutive weeks. The main hypothesis is that daily prospective observation (EMA) will reveal a higher and more fluctuating burden of disease compared to traditional retrospective scales, providing a more accurate representation of the impact of HAE on patients' daily lives.",[80,27,28],"Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",[59,82,83,84],"Burden of disease","Ecological Momentary Assessment","Quality of Life","2026-03-03",{"date":87,"type":38},"2026-03-04",{"date":89,"type":38},"2026-02-23",{"date":91,"type":20},"2027-02-28",{"name":93,"class":94},"Istituti Clinici Scientifici Maugeri SpA","OTHER",1]